| 1.105 -0.01 (-0.9%) | 11-07 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.51 |
1-year : | 1.69 |
| Resists | First : | 1.3 |
Second : | 1.45 |
| Pivot price | 1.24 |
|||
| Supports | First : | 1.05 |
Second : | 0.88 |
| MAs | MA(5) : | 1.14 |
MA(20) : | 1.26 |
| MA(100) : | 1.46 |
MA(250) : | 5.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7  |
D(3) : | 8.6 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 18.89 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OGEN ] has closed above bottom band by 8.4%. Bollinger Bands are 61.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.12 - 1.13 | 1.13 - 1.14 |
| Low: | 1.04 - 1.05 | 1.05 - 1.06 |
| Close: | 1.09 - 1.1 | 1.1 - 1.12 |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Sat, 08 Nov 2025
Oragenics: Q3 Earnings Snapshot - New Haven Register
Tue, 21 Oct 2025
Oragenics (NYSE American: OGEN) regains compliance as $16.5M Series H restores equity - Stock Titan
Tue, 07 Oct 2025
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Stock Titan
Tue, 02 Sep 2025
Oragenics appoints Natasha Giordano to board of directors - Investing.com
Wed, 16 Jul 2025
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - Yahoo Finance
Tue, 01 Jul 2025
Oragenics (OGEN) Announces $20M Stock Placement Deal - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 4.72e+006 (%) |
| Held by Institutions | 12 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.964e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -263 % |
| Return on Assets (ttm) | 285.1 % |
| Return on Equity (ttm) | -219.9 % |
| Qtrly Rev. Growth | 7470 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -947.34 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -10.61 |
| Dividend | 0 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|